<DOC>
	<DOCNO>NCT00924469</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy abiraterone acetate plus leuprolide acetate prednisone , versus leuprolide acetate alone male participant prostate cancer ( disease cell prostate gland become abnormal start grow uncontrollably , form tumor ) suitable candidate prostatectomy ( surgery remove part prostate gland ) .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety Efficacy Abiraterone Acetate Male Participants With Prostate Cancer</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( study drug assign chance ) , multi-center ( conducted one center ) study abiraterone male participant prostate cancer . The duration study approximately 24-32 week per participant . The study consist 4 part : Screening ( , 30 day study commences Day 1 ) ; Treatment ( abiraterone acetate 1000 milligram per day leuprolide acetate 22.5 milligram intramuscular injection [ injection substance muscle ] prednisone 5 mg daily ) ; Prostatectomy ( Week 24 ) ; Follow-up ( 4-8 week prostatectomy ) . Participants receive either abiraterone , leuprolide prednisone 24 week ( , Group 1 ) leuprolide every 12 week Week 24 abiraterone prednisone Week 13 24 ( , Group 2 ) . All eligible participant randomly assign 1 2 treatment group . Efficacy evaluate primarily concentration testosterone dihydrotestosterone prostate tissue Week 12 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate At least three core biopsy positive prostate cancer ( minimum 6 core biopsy must obtain baseline ) . A prostate biopsy within 6 month Screening allow entry requirement At least one follow feature : prostate specific antigen ( PSA ) great ( &gt; ) 10 nanogram per milliliter ( ng/ml ) ; PSA velocity &gt; 2 ng/ml per /year ( define rise PSA &gt; 2 ng/ml precede 12 month period ) ; Gleason score great equal ( &gt; = ) 7 ( 4+3 ) ; Gleason score 6 either PSA &gt; =10 ng/ml PSA velocity &gt; =2 ng/ml/year Serum testosterone &gt; 200 nanogram/deciliter Participant urologist must agree participant suitable prostatectomy Serious uncontrolled coexistent , nonmalignant disease , include active uncontrolled infection Abnormal liver function consist follow : serum bilirubin &gt; = 1.5 * upper limit normal ( ULN ) ; aspartate aminotransferase alanine aminotransferase &gt; =2.5 * ULN Uncontrolled hypertension within Screening period ( systolic blood pressure &gt; = 160 millimeter mercury [ mmHg ] diastolic BP &gt; = 95 mmHg ) Requirement corticosteroid great equivalent 5 milligram prednisone daily Participants active symptomatic viral hepatitis chronic liver disease clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class IIIV heart disease cardiac ejection fraction measurement &lt; 50 percent Baseline history gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug history pituitary adrenal dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Leuprolide acetate</keyword>
	<keyword>Prednisone</keyword>
	<keyword>CB7630</keyword>
	<keyword>Testosterone</keyword>
</DOC>